Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.
Sutton R, Pozza LD, Khaw SL, Fraser C, Revesz T, Chamberlain J, Mitchell R, Trahair TN, Bateman CM, Venn NC, Law T, Ong E, Heatley SL, McClure BJ, Meyer C, Marschalek R, Henderson MJ, Cross S, White DL, Kotecha RS. Sutton R, et al. Among authors: bateman cm. Pediatr Blood Cancer. 2021 May;68(5):e28922. doi: 10.1002/pbc.28922. Epub 2021 Feb 26. Pediatr Blood Cancer. 2021. PMID: 33638292
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).
Tasian SK, Silverman LB, Whitlock JA, Sposto R, Loftus JP, Schafer ES, Schultz KR, Hutchinson RJ, Gaynon PS, Orgel E, Bateman CM, Cooper TM, Laetsch TW, Sulis ML, Chi YY, Malvar J, Wayne AS, Rheingold SR. Tasian SK, et al. Among authors: bateman cm. Haematologica. 2022 Oct 1;107(10):2295-2303. doi: 10.3324/haematol.2021.279520. Haematologica. 2022. PMID: 35112552 Free PMC article. Clinical Trial.
Late effects in survivors of infant acute lymphoblastic leukaemia-a study of the Australian and New Zealand Children's Haematology/Oncology Group.
Mironova D, Saraswati CM, Downie P, Lai CY, Cook E, Carruthers V, Moukhaiber P, Molloy F, Serov J, McKinnon E, Alvaro F, Osborn M, Revesz T, Prestidge T, Cross S, Bateman CM, Moore AS, Khaw SL, Mateos MK, Kotecha RS. Mironova D, et al. Among authors: bateman cm. Blood Cancer J. 2023 Sep 26;13(1):150. doi: 10.1038/s41408-023-00924-5. Blood Cancer J. 2023. PMID: 37752126 Free PMC article. No abstract available.
Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.
Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, Bateman CM, Anderson K, Chaplin T, Young BD, Harrison CJ, Kempski H, So CW, Ford AM, Greaves M. Kearney L, et al. Among authors: bateman cm. Blood. 2009 Jan 15;113(3):646-8. doi: 10.1182/blood-2008-08-170928. Epub 2008 Oct 16. Blood. 2009. PMID: 18927438 Free article.
Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia.
van Delft FW, Horsley S, Colman S, Anderson K, Bateman C, Kempski H, Zuna J, Eckert C, Saha V, Kearney L, Ford A, Greaves M. van Delft FW, et al. Blood. 2011 Jun 9;117(23):6247-54. doi: 10.1182/blood-2010-10-314674. Epub 2011 Apr 11. Blood. 2011. PMID: 21482711 Free article.
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, McGuire HM, Patrick E, Chan AS, McCaughan G, Myers N, Micklethwaite KP, Antonenas V, Selim AG, Ritchie D, Bateman CM, Shaw PJ, Blyth E, Gottlieb DJ. Jiang W, et al. Among authors: bateman cm. Blood Adv. 2022 Sep 13;6(17):4949-4966. doi: 10.1182/bloodadvances.2022007103. Blood Adv. 2022. PMID: 35819448 Free PMC article.
Genetic variegation of clonal architecture and propagating cells in leukaemia.
Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, Kearney L, Enver T, Greaves M. Anderson K, et al. Among authors: bateman cm. Nature. 2011 Jan 20;469(7330):356-61. doi: 10.1038/nature09650. Epub 2010 Dec 15. Nature. 2011. PMID: 21160474
Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant.
Gottlieb DJ, Sutrave G, Jiang W, Avdic S, Street JA, Simms R, Clancy LE, Antonenas V, Gloss BS, Bateman C, Bishop DC, Micklethwaite KP, Blyth E. Gottlieb DJ, et al. Am J Hematol. 2023 Jan;98(1):159-165. doi: 10.1002/ajh.26594. Epub 2022 May 20. Am J Hematol. 2023. PMID: 35560045 Free PMC article.
20 results